Alert detail
LCD L36386: MolDX: Breast Cancer Assay: Prosigna® — Noridian
What changed
Prosigna® assay improves billing for breast cancer testing.
Who’s affected: Oncology billing teams · Effective: April 22, 2021
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.